Evidence for the spread of human-derived mutant huntingtin protein in mice and non-human primates.


Journal

Neurobiology of disease
ISSN: 1095-953X
Titre abrégé: Neurobiol Dis
Pays: United States
ID NLM: 9500169

Informations de publication

Date de publication:
07 2020
Historique:
received: 13 02 2020
revised: 15 04 2020
accepted: 05 05 2020
pubmed: 19 5 2020
medline: 15 7 2021
entrez: 19 5 2020
Statut: ppublish

Résumé

In recent years, substantial evidence has emerged to suggest that spreading of pathological proteins contributes to disease pathology in numerous neurodegenerative disorders. Work from our laboratory and others have shown that, despite its strictly genetic nature, Huntington's disease (HD) may be another condition in which this mechanism contributes to pathology. In this study, we set out to determine if the mutant huntingtin protein (mHTT) present in post-mortem brain tissue derived from HD patients can induce pathology in mice and/or non-human primates. For this, we performed three distinct sets of experiments where homogenates were injected into the brains of adult a) Wild-type (WT) and b) BACHD mice or c) non-human primates. Neuropathological assessments revealed that, while changes in the endogenous huntingtin were not apparent, mHTT could spread between cellular elements and brain structures. Furthermore, behavioural differences only occurred in the animal model of HD which already overexpressed mHTT. Taken together, our results indicate that mHTT derived from human brains has only a limited capacity to propagate between cells and does not depict prion-like characteristics. This contrasts with recent work demonstrating that other forms of mHTT - such as fibrils of a pathological polyQ length or fibroblasts and induced pluripotent stem cells derived from HD cases - can indeed disseminate disease throughout the brain in a prion-like fashion.

Identifiants

pubmed: 32422281
pii: S0969-9961(20)30216-3
doi: 10.1016/j.nbd.2020.104941
pii:
doi:

Substances chimiques

HTT protein, human 0
Huntingtin Protein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

104941

Subventions

Organisme : CIHR
Pays : Canada

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no competing interest.

Auteurs

Philippe Gosset (P)

Centre de Recherche du CHU de Québec - Université Laval, Axe Neurosciences, Québec, QC G1V 4G2, Canada.

Alexander Maxan (A)

Centre de Recherche du CHU de Québec - Université Laval, Axe Neurosciences, Québec, QC G1V 4G2, Canada.

Melanie Alpaugh (M)

Centre de Recherche du CHU de Québec - Université Laval, Axe Neurosciences, Québec, QC G1V 4G2, Canada.

Ludivine Breger (L)

Université de Bordeaux, Institut des maladies neurodégénératives, UMR 5293, Bordeaux CNRS UMR 5293, France.

Benjamin Dehay (B)

Université de Bordeaux, Institut des maladies neurodégénératives, UMR 5293, Bordeaux CNRS UMR 5293, France.

Zhu Tao (Z)

Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China.

Zhang Ling (Z)

Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China.

Chuan Qin (C)

Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China. Electronic address: qinchuan@pumc.edu.cn.

Giulia Cisbani (G)

University of Toronto, Department of Nutritional Sciences, Toronto, ON M5S 1A8, Canada.

Nadia Fortin (N)

Centre de Recherche du CHU de Québec - Université Laval, Axe Neurosciences, Québec, QC G1V 4G2, Canada.

Jean-Paul G Vonsattel (JG)

New-York Brain Bank, Columbia University, New York, NY 10032, United States.

Steve Lacroix (S)

Centre de Recherche du CHU de Québec - Université Laval, Axe Neurosciences, Québec, QC G1V 4G2, Canada; Département de Médicine Moléculaire, Université Laval, Québec, QC G1K 0A6, Canada.

Abid Oueslati (A)

Centre de Recherche du CHU de Québec - Université Laval, Axe Neurosciences, Québec, QC G1V 4G2, Canada; Département de Médicine Moléculaire, Université Laval, Québec, QC G1K 0A6, Canada.

Erwan Bezard (E)

Université de Bordeaux, Institut des maladies neurodégénératives, UMR 5293, Bordeaux CNRS UMR 5293, France.

Francesca Cicchetti (F)

Centre de Recherche du CHU de Québec - Université Laval, Axe Neurosciences, Québec, QC G1V 4G2, Canada; Département de Psychiatrie & Neurosciences, Université Laval, Québec, QC G1K 0A6, Canada. Electronic address: francesca.cicchetti@crchudequebec.ulaval.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH